Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | REGN4018 |
Trade Name | |
Synonyms | REGN-4018|REGN 4018|Ubamatamab |
Drug Descriptions |
REGN4018 is a bispecific antibody that binds MUC16 (CA125) on tumor cells and CD3 on T-cells to stimulate T-cell killing of MUC16-expressing tumor cells (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1777, PMID: 31217340). |
DrugClasses | CD3 Antibody 99 MUC16 Targeted Therapy 10 |
CAS Registry Number | 2305629-50-7 |
NCIT ID | C153129 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cemiplimab + REGN4018 | Cemiplimab REGN4018 | 0 | 2 |
REGN4018 | REGN4018 | 0 | 2 |
REGN4018 + REGN5668 | REGN4018 REGN5668 | 0 | 1 |